David H F Teng

Title: Innovations in Cancer Research by David H F Teng

Introduction

David H F Teng is a notable inventor based in Salt Lake City, UT (US), recognized for his contributions to cancer research. He holds three patents that focus on tumor suppressor genes and their implications in human cancers. His work has significant potential for improving cancer diagnosis and therapy.

Latest Patents

One of Teng's latest patents involves the BRG1 gene, which is a tumor suppressor mutated in prostate and other cancer types. This invention relates to the connection between the BRG1 gene and human cancers, offering insights for diagnosis and prognosis. It also explores therapeutic options for cancers with BRG1 mutations, including gene therapy, protein replacement therapy, and protein mimetics. Another significant patent pertains to the TMPRSS2 gene, which is also a tumor suppressor. This invention similarly addresses the relationship of the TMPRSS2 gene to human cancers, providing avenues for diagnosis and therapy for mutations in this gene.

Career Highlights

Throughout his career, David H F Teng has worked with Myriad Genetics, Inc., where he has contributed to advancements in genetic research and cancer therapies. His expertise in the field has led to significant innovations that aim to enhance patient outcomes.

Collaborations

Teng has collaborated with notable colleagues, including Sean V Tavtigian and Alexander K C Wong. These partnerships have fostered a collaborative environment that promotes innovative research in cancer genetics.

Conclusion

David H F Teng's work in cancer research exemplifies the impact of innovative thinking in the medical field. His patents on tumor suppressor genes are paving the way for new diagnostic and therapeutic strategies in cancer treatment.